Mobilizing and evaluating anticancer T cells: pitfalls and solutions.

Détails

ID Serval
serval:BIB_C7F99ECA59E4
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Mobilizing and evaluating anticancer T cells: pitfalls and solutions.
Périodique
Expert Review of Vaccines
Auteur(s)
Robert-Tissot C., Nguyen L.T., Ohashi P.S., Speiser D.E.
ISSN
1744-8395 (Electronic)
ISSN-L
1476-0584
Statut éditorial
Publié
Date de publication
2013
Volume
12
Numéro
11
Pages
1325-1340
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublishReview
Résumé
Immunotherapy is a promising means to fight cancer, prompting a steady increase in clinical trials and correlative laboratory studies in this field. As antitumor T cells play central roles in immunity against malignant diseases, most immunotherapeutic protocols aim to induce and/or strengthen their function. Various treatment strategies have elicited encouraging clinical responses; however, major challenges have been uncovered that should be addressed in order to fully exploit the potential of immunotherapy. Here, we outline pitfalls for the mobilization of antitumor T cells and offer solutions to improve their therapeutic efficacy. We provide a critical perspective on the main methodologies used to characterize T-cell responses to cancer therapies, with a focus on discrepancies between T-cell attributes measured in vitro and protective responses in vivo. This review altogether provides recommendations to optimize the design of future clinical trials and highlights important considerations for the proficient analysis of clinical specimens available for research.
Pubmed
Web of science
Création de la notice
17/11/2013 19:18
Dernière modification de la notice
20/08/2019 16:43
Données d'usage